影像学无进展生存期作为转移性激素敏感性前列腺癌总生存期的替代终点:双变量荟萃分析
该双变量荟萃分析纳入31项随机对照试验的35个治疗比较,评估影像学无进展生存期(rPFS)作为转移性激素敏感性前列腺癌(mHSPC)总生存期(OS)替代终点的有效性。rPFS与OS的风险比相关性为0.95(95% CrI:0.75,1.00),替代阈值效应为0.55至0.71,满足NICE的95%替代有效性阈值,支持rPFS作为OS的可靠替代终点。
要点
- rPFS与OS的风险比相关性为0.95(95% CrI:0.75,1.00)。
- 替代阈值效应为0.55至0.71,取决于所预测的试验样本量。
- rPFS满足NICE的95%替代有效性阈值,可作为OS的可靠替代终点。
核心结论
- 推导的替代方程可基于报告的rPFS获益估算mHSPC的OS,满足NICE的95%替代有效性阈值。
- 这些发现支持rPFS作为OS的可靠替代终点,有助于预测未来mHSPC试验的OS获益。
研究设计与样本
- 系统文献综述识别截至2023年12月发表的mHSPC随机对照试验,报告rPFS风险比(HRrPFS)和OS风险比(HROS)。
- 使用双变量随机效应荟萃分析(BRMA)评估HRrPFS与HROS的相关性,采用留一交叉验证(LOOCV)评估预测有效性。
- 使用近期mHSPC试验样本量估算替代阈值效应(STE),即预测OS获益所需的最小rPFS获益。
- 敏感性分析包括:排除仅报告一个终点的试验、排除违反比例风险假设的HR、排除允许交叉的试验、研究不同的研究内相关性假设值。
- 主要分析纳入31项试验的35个治疗比较。
主要发现
- 估计的rPFS-OS相关性为0.95(95% CrI:0.75,1.00)。
- LOOCV确认HROS均在95%预测区间内。
- 估计的STE范围为0.55至0.71,取决于所预测的试验样本量。
- 敏感性分析产生强但略低于主要分析的相关性(0.87、0.89、0.91),交叉验证中报告的HROS完全覆盖。
- 增加研究内相关性略微降低研究间相关性。
关键数值与推荐
- rPFS-OS相关性为0.95(95% CrI:0.75,1.00)。
- STE范围为0.55至0.71。
- 敏感性分析相关性分别为0.87、0.89、0.91。
- 满足NICE的95%替代有效性阈值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Overall survival (OS) is the standard efficacy endpoint in various solid tumor trials; however, it requires longer follow-up time for assessment than potential intermediate endpoints. This study evaluated radiological progression-free survival (rPFS) as a surrogate for OS in metastatic hormone-sensitive prostate cancer (mHSPC) using aggregate-level data from randomized controlled trials (RCTs). METHODS: A systematic literature review identified mHSPC RCTs published through December 2023, reporting hazard ratios for rPFS (HRrPFS) and OS (HROS). Correlation between HRrPFS and HROS was assessed using bivariate random-effects meta-analysis (BRMA). Predictive validity was assessed with leave-one-out cross-validation (LOOCV). The surrogate threshold effect (STE), or minimum rPFS benefit predicting an OS benefit, was estimated using recent mHSPC trial sample sizes. Sensitivity analyses (1) omitted trials that had only one of the endpoints reported, (2) omitted HRs that violated proportional hazards assumptions, (3) omitted trials that allowed cross-over and (4) investigated different assumed values of the within-study correlation. RESULTS: The primary analysis included 35 treatment comparisons from 31 trials. The estimated rPFS-OS correlation was 0.95 (95 % CrI: 0.75, 1.00). LOOCV confirmed HROS were within 95 % prediction intervals. The estimated STE ranged from 0.55 to 0.71 depending on the trial size being predicted. Sensitivity analyses produced strong but slightly lower correlations (0.87, 0.89, 0.91) than the primary analysis, with full coverage of the reported HROS in cross validation. Increasing within-study correlation slightly reduced between-study correlation. CONCLUSIONS: The derived surrogacy equation enables OS estimation based on reported rPFS benefits in mHSPC, meeting NICE's 95 % surrogate validity threshold. These findings support rPFS as a reliable surrogate for OS, facilitating prediction of OS benefits in future mHSPC trials.
引用
- Shore N, Morgans AK, Boegemann M, et al. Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysis. Eur J Cancer. 2025. PMID: 40413878. doi:10.1016/j.ejca.2025.115513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。